In-hospital venous thromboembolism (VTE) causes significant morbidity and mortality in hospitalized patients. The objective of our study is to determine the time to in-hospital VTE based on baseline risk stratification.
Methods:
All adult patients admitted to a 900-bed academic tertiary referral hospital who developed a VTE during hospital admission from September 1, 2011, to June 30, 2015, were retrospectively analyzed. Patients were excluded if they were younger than 18 years or if the VTE was present on admission.
Results:
The cohort included 400 patients, 224 (56%) males, median age 66 years. The median time to VTE was 8 days. Significant differences in time to VTE existed between the risk groups.
Conclusion:
Time to VTE in a broad hospitalized patient population differs based on admission risk group. This finding highlights the importance of performing risk assessment upon admission and subsequently with clinical changes to assess increases in risk scores.
KhannaRMaynardGSadeghiB. Incidence of hospital-acquired venous thromboembolic codes in medical patients hospitalized in academic medical centers. J Hosp Med. 2014;9(4):221–225.
2.
MaynardGA. Preventing Hospital-Acquired Venous Thromboembolism: A Guide for Effective Quality Improvement. 2nd ed. Rockville, MD: Agency for Healthcare Research and Quality; August 2016. AHRQ Publication No. 16-0001-EF.
3.
CohenATTapsonVFBergmannJF; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387–394.
RaskobGESilversteinRBratzlerDW. Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med. 2010;38(4 suppl):S502–509.
6.
KahnSRMorrisonDRCohenJM. Interventions for implementation of thromboprophylaxis in hospitalized medical and surgical patients at risk for venous thromboembolism. Cochrane Database of Syst Rev. 2013;7. Art. No.: CD008201. DOI: 10.1002/14651858.CD008201.pub2.
7.
LauBDHautER. Practices to prevent venous thromboembolism: a brief review. BMJ Qual Saf. 2014;23(3):187–195.
8.
AndersonFAJrSpencerFA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 suppl 1):I9–I16.
9.
SpyropoulosACAndersonFAJrFitzgeraldG. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140(3):706–714.
10.
CapriniJAArcelusJIHastyJH. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991;17(suppl 3):304–312.
11.
BarbarSNoventaFRossettoV. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua prediction score. J Thromb Haemost. 2010;8(11):2450–2457.
12.
MahanCESpyropoulosAC. ASHP therapeutic position statement on the role of pharmacotherapy in preventing venous thromboembolism in hospitalized patients. Am J Health Syst Pharm. 2012;69(24):2174–2190.
13.
KahnSRLimWDunnAS. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e195S–e226S.
14.
GouldMKGarciaDAWrenSM. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e227S–e277S.
15.
Falck-YtterYFrancisCWJohansonNA. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e278S–e325S.
16.
GoldhaberSZTurpieAG. Prevention of venous thromboembolism among hospitalized medical patients. Circulation. 2005;111(1):e1–e3.
17.
SamamaMMCohenATDarmonJY. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341(11):793–800.
18.
LeizoroviczACohenATTurpieAG. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874–879.
19.
CohenATDavidsonBLGallusAS. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332(7537):325–329.
20.
HostlerDCMarxESMooresLK. Validation of the International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score. Chest. 2016;149(2):372–379.
21.
MaynardGAMorrisTAJenkinsIH. Optimizing prevention of hospital-acquired venous thromboembolism (VTE): prospective validation of a VTE risk assessment model. J Hosp Med. 2010;5(1):10–18.
22.
GalanterWLThambiMRosencranzH. Effects of clinical decision support on venous thromboembolism risk assessment, prophylaxis, and prevention at a university teaching hospital. Am J Health Syst Pharm. 2010;67(15):1265–1273.
23.
CroninMHillTReichDA. Implementation of a multidisciplinary, pharmacy-led, thromboprophylaxis program in total-joint arthroplasty patients. Am J Health Syst Pharm. 2009;66(2):171–175.
McClendonJJrSmithTRO’ShaughnessyBA. Time to event analysis for the development of venous thromboembolism after spinal fusion ≥ 5 levels. World Neurosurg. 2015;84(3):826–833.
26.
ClagettGPAndersonFAJrGeertsW. Prevention of venous thromboembolism. Chest. 1998;114(5 suppl):531S–560S.
27.
PatederDBGonzalesRAKebaishKM. Pulmonary embolism after adult spinal deformity surgery. Spine (Phila Pa 1976). 2008;33(3):301–305.
